Literature DB >> 18704441

Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?

Hashim Uddin Ahmed1, Mark Emberton.   

Abstract

INTRODUCTION: Focal therapy for prostate cancer is a radical paradigm shift in the management of men with localised prostate cancer. It involves locating and destroying only the areas of prostate cancer whilst leaving the majority of the prostate untreated. By doing so, it is proposed that side-effects of traditional whole-gland therapies such as impotence, incontinence and rectal toxicity will be significantly reduced and cancer control will be at similar levels. METHODS AND MATERIALS: A Medline/Pubmed search was conducted between 1 May 1998 and 1 May 2008 using the following terms: 'focal therapy', 'lumpectomy', 'hemiablation', 'laterality', 'multifocal', 'unifocal' and 'index lesion' alongside 'prostate cancer'. Articles were selected for their relevance to this review. Abstracts from international conferences over the last 5 years were also used where appropriate. Authors' personal bibliography was used to supplement the review.
CONCLUSIONS: A number of case series have reported significantly lower incontinence and impotence rates using focal cryoablation and one series on focal HIFU. The reporting quality has been variable and there are currently ongoing clinical trials with IRB approval in the USA and UK. Long term follow-up is required. Focal therapy is an exciting new area of research that could hold great promise for men with localised low to intermediate risk prostate cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18704441     DOI: 10.1007/s00345-008-0317-5

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  90 in total

1.  Focal therapy in prostate cancer: future trends.

Authors:  Al Barqawi; E David Crawford
Journal:  BJU Int       Date:  2005-02       Impact factor: 5.588

2.  Clinical and pathological characteristics of unstageable prostate cancer: analysis of the CaPSURE database.

Authors:  Peter Langenstroer; Peter Carroll; J Brantley Thrasher
Journal:  J Urol       Date:  2005-07       Impact factor: 7.450

3.  Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening.

Authors:  R M Merrill; R A Stephenson
Journal:  J Urol       Date:  2000-02       Impact factor: 7.450

4.  Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer.

Authors:  Steven B Zeliadt; Scott D Ramsey; David F Penson; Ingrid J Hall; Donatus U Ekwueme; Leonard Stroud; Judith W Lee
Journal:  Cancer       Date:  2006-05-01       Impact factor: 6.860

Review 5.  How good is MRI at detecting and characterising cancer within the prostate?

Authors:  Alexander P S Kirkham; Mark Emberton; Clare Allen
Journal:  Eur Urol       Date:  2006-06-30       Impact factor: 20.096

6.  Natural history of early, localized prostate cancer.

Authors:  Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

7.  Pathological characteristics of prostate cancer detected through prostate specific antigen based screening.

Authors:  Stacy Loeb; Chris M Gonzalez; Kimberly A Roehl; Misop Han; Jo Ann V Antenor; Ronald L Yap; William J Catalona
Journal:  J Urol       Date:  2006-03       Impact factor: 7.450

8.  Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results.

Authors:  David S Ellis; Theodore B Manny; John C Rewcastle
Journal:  Urology       Date:  2007-12       Impact factor: 2.649

Review 9.  Cancer biomarkers: knowing the present and predicting the future.

Authors:  Sabarni K Chatterjee; Bruce R Zetter
Journal:  Future Oncol       Date:  2005-02       Impact factor: 3.404

10.  The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance.

Authors:  David M Latini; Stacey L Hart; Sara J Knight; Janet E Cowan; Phillip L Ross; Janeen Duchane; Peter R Carroll
Journal:  J Urol       Date:  2007-07-16       Impact factor: 7.450

View more
  8 in total

1.  Prostate cancer diagnosis: the feasibility of needle-based optical coherence tomography.

Authors:  Berrend G Muller; Daniel M de Bruin; Willemien van den Bos; Martin J Brandt; Juliette F Velu; Mieke T J Bus; Dirk J Faber; Dilara Savci; Patricia J Zondervan; Theo M de Reijke; Pilar Laguna Pes; Jean de la Rosette; Ton G van Leeuwen
Journal:  J Med Imaging (Bellingham)       Date:  2015-07-09

Review 2.  Imaging modalities in focal therapy: patient selection, treatment guidance, and follow-up.

Authors:  Berrend G Muller; Willemien van den Bos; Peter A Pinto; Jean J de la Rosette
Journal:  Curr Opin Urol       Date:  2014-05       Impact factor: 2.309

3.  Hemiablation of Localized Prostate Cancer by High-Intensity Focused Ultrasound: A Series of 35 Cases.

Authors:  Peter V Glybochko; Alexander V Amosov; German E Krupinov; Nikolay V Petrovskii; Ilya S Lumpov
Journal:  Oncology       Date:  2019-05-09       Impact factor: 2.935

4.  Outcomes of active surveillance for men with intermediate-risk prostate cancer.

Authors:  Matthew R Cooperberg; Janet E Cowan; Joan F Hilton; Adam C Reese; Harras B Zaid; Sima P Porten; Katsuto Shinohara; Maxwell V Meng; Kirsten L Greene; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-11-29       Impact factor: 44.544

Review 5.  Pathologic basis of focal therapy for early-stage prostate cancer.

Authors:  Vladimir Mouraviev; Janice M Mayes; Thomas J Polascik
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

6.  Endorectal MRI and MR spectroscopic imaging of prostate cancer: developing selection criteria for MR-guided focal therapy.

Authors:  Stephanie T Chang; Antonio C Westphalen; Priyanka Jha; Adam J Jung; Peter R Carroll; John Kurhanewicz; Fergus V Coakley
Journal:  J Magn Reson Imaging       Date:  2013-05-16       Impact factor: 4.813

7.  Customized Tool for the Validation of Optical Coherence Tomography in Differentiation of Prostate Cancer.

Authors:  B G Muller; A Swaan; D M de Bruin; W van den Bos; A W Schreurs; D J Faber; E C H Zwartkruis; L Rozendaal; A N Vis; J A Nieuwenhuijzen; R J A van Moorselaar; T G van Leeuwen; J J M C H de la Rosette
Journal:  Technol Cancer Res Treat       Date:  2016-07-07

Review 8.  Tumor focality in prostate cancer: implications for focal therapy.

Authors:  Markos Karavitakis; Hashim U Ahmed; Paul D Abel; Steven Hazell; Mathias H Winkler
Journal:  Nat Rev Clin Oncol       Date:  2010-11-23       Impact factor: 66.675

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.